ClinicalTrials.gg
CompletedNCT03492580Updated Jun 25, 2025

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

An observational study in Diabetes Mellitus, Type 2 and Cardiovascular Diseases, sponsored by Janssen Research & Development, LLC. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
714,582
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Johnson & Johnson.

Started
2018
with 1 other
Observational
8 of 62
none open now
Registered
61st of 62
by date

Among the 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson, this one is one of 2 that started in 2018, is one of 8 observational ones, and was the 61st registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson as a file.
02

Study summary

The primary purpose of study is to estimate the incidence and comparative effect on health outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation. The date of first exposure to the particular drug(s) in the database, where the exposure start is between 1-April-2013 to 15-May-2017 and outcome data for these participants will be analyzed and reported in this study.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Cardiovascular Diseases
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants diagnosed with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease over a 4-year period 1 April 2013 and 15 May 2017 will be observed.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First exposure to the particular drug(s) in database (index date)
  • Exposure start is between 1 April 2013 and 15 May 2017
  • At least 365 days of continuous observation time prior to index
  • At least 1 condition occurrence of 'Type II diabetes' any time in the prior continuous observation time (which is at least 365 days long) before or on the index date (first exposure to the particular drug(s) in database)

For cohort with 'established cardiovascular disease - At least 1 occurrence of 'conditions indicating established cardiovascular disease' on or any time in the prior continuous observation time (which is at least 365 days long) prior to the index date

Exclusion criteria

Exclusion Criteria:

- Participants with type 1 diabetes or secondary diabetes prior to or on the index date of exposure were excluded from the study

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
714,582 participants (actual)
Patient registry
No

Groups and cohorts

  • Cohort 1: Canagliflozin

    A target cohort which includes new users of canagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. Truven Health MarketScan Commercial Claims and Encounters Database (CCAE) 2. Truven Health MarketScan Medicare Supplemental and Coordination of Benefits Database (MDCR) 3. Truven Health MarketScan Multi-state Medicaid Database (MDCD) 4. OptumInsight's de-identified Clinformatics Datamart, Extended-Date of Death (Optum).

    Drug: Canagliflozin

  • Cohort 2: Canagliflozin with Cardiovascular Disease (CVD)

    A target cohort which includes new users of canagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.

    Drug: Canagliflozin

  • Cohort 3: Empagliflozin

    A comparator cohort which includes new users of empagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.

    Drug: Empagliflozin

  • Cohort 4: Empagliflozin with CVD

    A comparator cohort which includes new users of empagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.

    Drug: Empagliflozin

  • Cohort 5: Dapagliflozin

    A comparator cohort which includes new users of dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.

    Drug: Dapagliflozin

  • Cohort 6: Dapagliflozin with CVD

    A comparator cohort which includes new users of dapagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.

    Drug: Dapagliflozin

  • Cohort 7: Empagliflozin or Dapagliflozin

    A target cohort which includes new users of empagliflozin or dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.

    Drug: Empagliflozin · Drug: Dapagliflozin

  • Cohort 8: Empagliflozin or Dapagliflozin with CVD

    A target cohort which includes new users of empagliflozin or dapagliflozin with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.

    Drug: Empagliflozin · Drug: Dapagliflozin

  • Cohort 9: DPP-4 inhibitor (i)/ GLP-1 agonist (a)/ other AHA

    A comparator cohort which includes new users of any dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonist, or other select antihyperglycemic agents (AHA) for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.

    Drug: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors · Drug: Glucagon-like Peptide-1 (GLP-1) Agonist · Drug: Anti-hyperglycemic Agents (AHA)

  • Cohort 10: DPP-4 (i)/ GLP-1 (a)/ other AHA with CVD

    A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.

    Drug: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors · Drug: Glucagon-like Peptide-1 (GLP-1) Agonist · Drug: Anti-hyperglycemic Agents (AHA)

  • Cohort 11: DPP-4 (i),GLP-1 (a),TZD, SU, insulin, other AHA

    A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, thiazolidinediones (TZD), sulfonylureas (SU), insulin, or other select AHA for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.

    Drug: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors · Drug: Glucagon-like Peptide-1 (GLP-1) Agonist · Drug: Anti-hyperglycemic Agents (AHA) · Drug: Thiazolidinediones (TZD) · Drug: Sulfonylureas (SU) · Drug: Insulin

  • Cohort 12: DPP-4(i), GLP-1(a), TZD, SU, insulin, AHA with CVD

    A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.

    Drug: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors · Drug: Glucagon-like Peptide-1 (GLP-1) Agonist · Drug: Anti-hyperglycemic Agents (AHA) · Drug: Thiazolidinediones (TZD) · Drug: Sulfonylureas (SU) · Drug: Insulin

Interventions

  • No intervention or treatment assignment imposed by this study. Participants received canagliflozin as a part of routine clinical practice.

  • No intervention or treatment assignment imposed by this study. Participants received empagliflozin as a part of routine clinical practice.

  • No intervention or treatment assignment imposed by this study. Participants received dapagliflozin as a part of routine clinical practice.

  • DrugDipeptidyl Peptidase 4Studies of Dipeptidyl Peptidase 4Dipeptidyl Peptidase 4 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    No intervention or treatment assignment imposed by this study. Participants received DPP-4 inhibitor as a part of routine clinical practice. DPP-4 inhibitors includes: alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin.

  • DrugGlucagon-Like Peptide 1Studies of Glucagon-Like Peptide 1Glucagon-Like Peptide 1 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    No intervention or treatment assignment imposed by this study. Participants received GLP-1 agonist as a part of routine clinical practice. GLP-1 agonists includes: albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide.

  • DrugAnti-hyperglycemic Agents (AHA)

    No intervention or treatment assignment imposed by this study. Participants received other selected AHA as a part of routine clinical practice. Other select AHAs includes: acarbose, bromocriptine, miglitol, nateglinide, repaglinide.

  • DrugThiazolidinediones (TZD)

    No intervention or treatment assignment imposed by this study. Participants received TZD as a part of routine clinical practice. TZDs includes: pioglitazone, rosiglitazone, troglitazone.

  • DrugSulfonylureas (SU)

    No intervention or treatment assignment imposed by this study. Participants received SU as a part of routine clinical practice. SUs includes: glipizide, glyburide, glimepiride, chlorpropamide, tolazamide, tolbutamide, acetohexamide

  • No intervention or treatment assignment imposed by this study. Participants received Insulin as a part of routine clinical practice.

06

What researchers measure

Primary outcomes

  1. Number of Hospitalizations for Heart Failure

    Number of hospital admissions with a primary diagnosis of 'heart failure' will be reported.

    Time frame: Approximately 4-years

  2. Number of Participants with Below Knee Lower Extremity Amputation Events

    Number of participants with new below-knee lower extremity amputation procedures, excluding recent (within 30 day) revisions will be reported.

    Time frame: Approximately 4-years

07

Study locations

1 site
  • Janssen Investigative Site
    Titusville, New Jersey 08560, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Apr 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2018
First posted
Apr 10, 2018
StartActual
Feb 22, 2018
Primary completionActual
Apr 6, 2018
CompletionActual
Jun 25, 2018
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03492580
Responsible party
Sponsor
First posted
Apr 10, 2018
Start date
Feb 22, 2018
Primary completion
Apr 6, 2018
Completion
Jun 25, 2018
Last update
Jun 25, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion